critique of a nanoparticle cancer therapy model

43
Paper Critique Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical Model T. Stylianopoulos, K. Soteriou, D. Fukumura, R. Jain Presented by: Nils Persson

Upload: nils-persson

Post on 01-Jun-2015

233 views

Category:

Science


1 download

DESCRIPTION

A scientific critique of a computational fluid dynamics and mass transport model describing nanoparticle flux into a tumor. Methods and results are briefly described, followed by a point by point critique of the author's methods, conclusions, and the paper's significance.

TRANSCRIPT

Page 1: Critique of a nanoparticle cancer therapy model

Paper CritiqueCationic Nanoparticles Have Superior Transvascular Flux into Solid

Tumors: Insights from a Mathematical Model

T. Stylianopoulos, K. Soteriou, D. Fukumura, R. Jain

Presented by: Nils Persson

Page 2: Critique of a nanoparticle cancer therapy model

2

Challenge

• Deliver nanoparticles into the tumor interstitium uniformly and selectively

• Resistances to this goal:– Flow through capillaries– Flow through capillary pores– Diffusion through interstitium– Drainage to normal tissue

Page 3: Critique of a nanoparticle cancer therapy model

3

Structure of the Model

Capillary – Hagen Poiseuille flowConvection only

PoresHindered

stokesflow

TumorPorous flow and diffusion

No drainageNormal tissueP = 0

DiffusionConvection

Grid 1

Grid 2

Page 4: Critique of a nanoparticle cancer therapy model

4

Structure of the Model

Capillary – Hagen Poiseuille flowConvection only

TumorPorous flow and diffusion

No drainageNormal tissueP = 0

DiffusionConvection

Grid 1

Grid 2

PoresHindered

stokesflow

Page 5: Critique of a nanoparticle cancer therapy model

5

Structure of the Model

Capillary – Hagen Poiseuille flowConvection only

TumorPorous flow and diffusion

No drainageNormal tissueP = 0

DiffusionConvection

Grid 1

Grid 2

Effect of charge,Ionic strength,Pore size

PoresHindered

stokesflow

Page 6: Critique of a nanoparticle cancer therapy model

6

Two steps: Pressure, then Concentration

• Steady state pressure profile

Page 7: Critique of a nanoparticle cancer therapy model

7

Capillary – Hagen Poiseuille flowConvection only

TumorPorous flow and diffusion

No drainageNormal tissueP = 0

DiffusionConvection

Grid 1

Grid 2

Two steps: Pressure, then Concentration

PoresHindered

stokesflow

Page 8: Critique of a nanoparticle cancer therapy model

8

Two steps: Pressure, then Concentration

• RK4 time stepping with centered finite differences to solve C(r,t)– Not reported, most interesting result

• Figure of merit: Vascular permeability or transvascular flux, Peff

– Similar to a mass transfer coefficient into tumor:

Averaged concentration, C

Page 9: Critique of a nanoparticle cancer therapy model

9

Representative Results

Fluid in tumor stagnatesPore diameter is too restrictive

Peff

Page 10: Critique of a nanoparticle cancer therapy model

10

Critiques• Blood viscosity/compressibility• Capillary Compliance• Dilute particle assumption• Concentration BCs unspecified and unrealistic• Transvascular flux is over-fit• Deen’s theory is shaky for attractive charges• Centerline approximation invalid for attractive charges• “lacking information” on glycocalyx charge, the crux of the entire

paper• Neglected axial diffusion even in areas of zero flow• 2-dimensional percolation network was unnecessary to obtain results• Lead author did not apply results of a previous modeling study

Page 11: Critique of a nanoparticle cancer therapy model

11

Critiques• Blood viscosity/compressibility• Capillary Compliance• Dilute particle assumption• Concentration BCs unspecified and unrealistic• Transvascular flux is over-fit• Deen’s theory is shaky for attractive charges• Centerline approximation invalid for attractive charges• “lacking information” on glycocalyx charge, the crux of the entire

paper• Neglected axial diffusion even in areas of zero flow• 2-dimensional percolation network was unnecessary to obtain results• Lead author did not apply results of a previous modeling study

Page 12: Critique of a nanoparticle cancer therapy model

12

Blood Flow

• Modeled with Hagen-Poiseuille equation– Assumes laminar flow, smooth pipe, constant density and viscosity

(3 mmHg-s = 4 mPa-s)

• Properties of blood:– Viscoelastic: erythrocyte deformability and aggregation– Shear thinning– Viscosity varies with hematocrit level

• Plasma:– Newtonian– µ = 1.2 mPa-s (water = 0.65 mPa-s @ 37 °C)

Page 13: Critique of a nanoparticle cancer therapy model

13

Dilute Particle Assumption

• Deen’s theory assumes no solute-solute interactions (continuous solvent)

• Nanoparticles are in pores with plasma, concentration of albumin (~10 nm) is about 0.5 wt%

• Deen predicts ~10% higher partitioning into pores at this concentration

Page 14: Critique of a nanoparticle cancer therapy model

14

Where does Deen’s theory break down?

• “Only for attractive interactions (E<0) is there likely to be a problem.” – Deen, 1987

• Hindrance integrals blow up

Page 15: Critique of a nanoparticle cancer therapy model

15

The Centerline Approximation

• Says that hindrance coefficients are those of r=0– Very good for repulsive charges– Very bad for attractive charges

- - - - - -

- - - - - -

Deen, 1987

Page 16: Critique of a nanoparticle cancer therapy model

16

The glycocalyx – source of charge• Layer of carbohydrates on

inner wall of capillary– But, in pores?

• Negatively charged, ~-0.022 C/m21

-used -0.05 C/m2

• 0.5 µm thick – too thick for capillary pores

• Acts as molecular sieve and shear stress transducer

1Donath et al., 1996, image Reitsma et al., 2007

Page 17: Critique of a nanoparticle cancer therapy model

17

Previous Studies

• Campbell and Jain et al., 2002– Tumor uptake not affected by charge, however,

accumulation in tumor vessels doubled for cationic particles

• Stylianopoulos, et al., 2010– Positive charge hinders

diffusion in the interstitium– Not applied to this model

Page 18: Critique of a nanoparticle cancer therapy model

18

Conclusions

• Very powerful model used to study known charge phenomena– Many bad approximations, missing data

• Much greater insight is provided on the transport phenomena and pore size distributions

• Slight modifications could yield very realistic results

Page 19: Critique of a nanoparticle cancer therapy model

19

Dimensionless Quantities, 400nm pores, 60nm particles

DiffusionConvection

Grid 1

Grid 2

D ~ 10-13 m2/s= 10-9 cm2/s

V:4E-5 m/sPe,r = 9Pe,L = 220Re = 4E-6∆P = 1.25 mmHg

V:2.5E-4 m/sPe,r = 53Pe,L = 1300Re = 2.5E-5∆P = 7.5 mmHg

5µm

15µm

V:2.3E-4 m/sPe,L = 2.3E6Re = 8.6E-4∆P = 20 mmHg (max)

V:2E-6 cm/sPe,L = 100Re << 1∆P = 1.25 mmHg“L” = 0.5cm

Assumes Ac is void surface area

V:2.4E-5 cm/sPe,L = 600Re << 1∆P = 7.5 mmHg“L” = 0.25cm

Page 20: Critique of a nanoparticle cancer therapy model

20

Reynolds Number in Pores… <<1∆P = 0.05 = 1.25 mmHg ∆P = 0.3 = 7.5 mmHg

166.6 Pa 999.7 PaR (nm) R (m) v (m/s) Re v (m/s) Re

10 1.00E-08 1.0E-07 5.2E-10 6.2E-07 3.1E-0950 5.00E-08 2.6E-06 6.5E-08 1.6E-05 3.9E-07

100 1.00E-07 1.0E-05 5.2E-07 6.2E-05 3.1E-06150 1.50E-07 2.3E-05 1.8E-06 1.4E-04 1.1E-05200 2.00E-07 4.2E-05 4.2E-06 2.5E-04 2.5E-05250 2.50E-07 6.5E-05 8.1E-06 3.9E-04 4.9E-05300 3.00E-07 9.4E-05 1.4E-05 5.6E-04 8.4E-05350 3.50E-07 1.3E-04 2.2E-05 7.7E-04 1.3E-04400 4.00E-07 1.7E-04 3.3E-05 1.0E-03 2.0E-04450 4.50E-07 2.1E-04 4.7E-05 1.3E-03 2.8E-04500 5.00E-07 2.6E-04 6.5E-05 1.6E-03 3.9E-04

Page 21: Critique of a nanoparticle cancer therapy model

21

Peclet Numbers in Pores… >>1

∆P = 1.25 mmHg ∆P = 7.5 mmHg166.61 Pa 999.67 Pa

R (nm) R (m) v (m/s) D(m^2/s) Pe, r Pe,L v (m/s) D(m^2/s) Pe, r Pe,L10 1.00E-08 1.0E-07 1.89E-11 5.5E-05 2.8E-02 6.2E-07 1.89E-11 3.3E-04 1.7E-0150 5.00E-08 2.6E-06 3.78E-12 3.4E-02 3.4E+00 1.6E-05 3.78E-12 2.1E-01 2.1E+01

100 1.00E-07 1.0E-05 1.89E-12 5.5E-01 2.8E+01 6.2E-05 1.89E-12 3.3E+00 1.7E+02150 1.50E-07 2.3E-05 1.26E-12 2.8E+00 9.3E+01 1.4E-04 1.26E-12 1.7E+01 5.6E+02200 2.00E-07 4.2E-05 9.46E-13 8.8E+00 2.2E+02 2.5E-04 9.46E-13 5.3E+01 1.3E+03250 2.50E-07 6.5E-05 7.57E-13 2.2E+01 4.3E+02 3.9E-04 7.57E-13 1.3E+02 2.6E+03300 3.00E-07 9.4E-05 6.30E-13 4.5E+01 7.4E+02 5.6E-04 6.30E-13 2.7E+02 4.5E+03350 3.50E-07 1.3E-04 5.40E-13 8.3E+01 1.2E+03 7.7E-04 5.40E-13 5.0E+02 7.1E+03400 4.00E-07 1.7E-04 4.73E-13 1.4E+02 1.8E+03 1.0E-03 4.73E-13 8.5E+02 1.1E+04450 4.50E-07 2.1E-04 4.20E-13 2.3E+02 2.5E+03 1.3E-03 4.20E-13 1.4E+03 1.5E+04500 5.00E-07 2.6E-04 3.78E-13 3.4E+02 3.4E+03 1.6E-03 3.78E-13 2.1E+03 2.1E+04

Assumes γ=0.3 (similar to paper)Assumes Stokes-Einstein diffusivityAssumes Hagen-Poiseuille velocity in pores

Page 22: Critique of a nanoparticle cancer therapy model

22

Data

Page 23: Critique of a nanoparticle cancer therapy model

23

Ionic Strength

• I (mol/kg) = ½ Σmizi2

– Seawater: 0.72 mol/kg– In paper: varied from 0 to 0.15M

• Debye length κ-1 ~ I-1/2

– 1 nm• ln γ ~ κ ~ I1/2

Increased concentration = decreased Debye length = lower potential

Debye LengthsI K-1 (m) e0 8.85E-12

0.005 4.38E-09 eR 780.01 3.10E-09 R 8.3140.06 1.26E-09 T 3100.15 7.99E-10 dS 1000

Na 6.02E+23e 1.60E-19

Page 24: Critique of a nanoparticle cancer therapy model

24

H and W for negative particles

Lambda = 0.3I = 0.15

3

Page 25: Critique of a nanoparticle cancer therapy model

25

Flux of negatively charged particles

Q = -.05

Lambda = 0.3

Both 400nm/60nm

4

Page 26: Critique of a nanoparticle cancer therapy model

26

More negative charge fluxes

positive

NegativeI = .15

5

400nm/60nm

Page 27: Critique of a nanoparticle cancer therapy model

27

Varying pore size

Page 28: Critique of a nanoparticle cancer therapy model

28

Fitting the Vascular Permeability

• C(t) linear – why?

• They fit an exponential0

100200

300400

500600

700800

9001000

0.00

0.05

0.10

0.15

0.20

0.25

f(x) = 0.0002199202 x + 0.00040044141R² = 0.999948648166217

Time (sec)

Dim

ensi

onle

ss C

on-

cent

ratio

n

Source: Data Thief

Large Kd yields vastly simpler eqn.Kd ~ 80,000

Page 29: Critique of a nanoparticle cancer therapy model

29

No flowpredicted

Page 30: Critique of a nanoparticle cancer therapy model

30

No flow to the tumor

Wu et al. 2008

- Also predicted by a paper they cite

- Nanoparticles reach tumor’s edge, then spill out

- This paper also treats viscosity as a function of hematocrit

Page 31: Critique of a nanoparticle cancer therapy model

31

Transport Properties of a Tumor

Chauhan et al. 2011

Page 32: Critique of a nanoparticle cancer therapy model

32

Starling’s Law

• Jv = Kf([Pc-Pi]-σ[πc-πi])• σ = reflection coef.– More likely varies with pore size– Human serum albumin: ~10nm in diameter

• Assumes Hagen-Poiseuille flow in pore• R = 200 nm, µ = 4 Pa-s, ∆P varies, L = 5 µm• ∆P is normalized to 25 mmHg

Page 33: Critique of a nanoparticle cancer therapy model

33

Vascular Equations

Hagen - Poiseuille

Mass balance, missing transvascular loss

- ϕ

Page 34: Critique of a nanoparticle cancer therapy model

34

Interstitial Equations

+ ϕTumor mass balane:

Pe ~ 800 in the interstitium

Transvascular“generation” term

Darcy’s Law, Ac = void surface area Ac = pi*d/Sv

Page 35: Critique of a nanoparticle cancer therapy model

35

Transvascular Equations

S = inner surface area of vessel

L = thickness of capillary wall

For steady state

R (nm) Lp (m^3/s/Pa/m^2) and in cm/mmHg v (m/s)10 1.88E-10 2.50E-06 6.25E-0750 4.69E-09 6.25E-05 1.56E-05

100 1.88E-08 2.50E-04 6.25E-05150 4.22E-08 5.62E-04 1.41E-04200 7.50E-08 1.00E-03 2.50E-04250 1.17E-07 1.56E-03 3.91E-04300 1.69E-07 2.25E-03 5.63E-04350 2.30E-07 3.06E-03 7.66E-04400 3.00E-07 4.00E-03 1.00E-03450 3.80E-07 5.06E-03 1.27E-03500 4.69E-07 6.25E-03 1.56E-03

Page 36: Critique of a nanoparticle cancer therapy model

36

Transvascular EquationsQt

FluxMass/time*area

Flowmass/time

W = convective hindranceH = diffusive hindrance

1-σ=WDerived from…

Page 37: Critique of a nanoparticle cancer therapy model

37

Hindrance Factors

diffusive

convective pore

Centerline:Pull out K-1 and GAs constants

τ=κ

Page 38: Critique of a nanoparticle cancer therapy model

38

Derivation of Partition Coefficients

Drag forceDiffusive force

• N = U*C• Poiseuille velocity profile• Average flux over pore area• Assume C(z,β) separable• Neglect Taylor dispersion• Radial Pe > 2• Axial Pe >29• Both are satisfied (See table)

Page 39: Critique of a nanoparticle cancer therapy model

39

Runge-Kutta 4th Order

Industry standard, O(h5) error

Page 40: Critique of a nanoparticle cancer therapy model

40

Transport through pores

• Assumptions:– low Re <1, Per>>1 (samples all radii)– dilute in fluid continuum (?)– significant radius relative to pore– no Taylor dispersion (Per>2, PeL>29)– fully developed flow

• Diffusion and hydrodynamic drag forces

Smith & Deen, 1982

Page 41: Critique of a nanoparticle cancer therapy model

41

Length Scales

• RBC: D = 8 µm• Human serum albumin: 10 nm• Nanomedicines: 10 – 100 nm– In paper: 6 – 200 nm, usually 0.3*Dp

• Capillaries: 10 µm (15 µm in paper)• Vascular pores: 1-1000 nm– In paper: 400 nm average, distribution

Page 42: Critique of a nanoparticle cancer therapy model

42

Vascular Network

• 200x200 two-layer grid, each point is defined by the neighbors to which it connects

• Volumetric flow conserved through each point• Vasculature only exists at pre-defined points• Interstitium occupies all grid points inside radius

Page 43: Critique of a nanoparticle cancer therapy model

43

Overview of Tumor Modeling

Wu et al. 2007